NewsSTAT
Ranked by formulaVerdict: RoutineSTAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down
Recent deaths are setbacks in drug companies’ interest in applying cancer therapy strategies to autoimmune diseases.
Score█████░░░░░5.1
Caveats
- Not randomized: its findings are associations.
VerdictCompetent work. Briefs at most.
Summary from the source
Recent deaths are setbacks in drug companies’ interest in applying cancer therapy strategies to autoimmune diseases.
The editor's rubric
- Leverage2 / 5
- Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
- Magnitude2 / 5
- Solid incremental gain on a meaningful problem.
- Evidence2 / 5
- Limited: single setting, weak baselines, or an observational association presented as causal.
- Novelty1 / 5
- A minor twist on a known approach.
- Trajectory2 / 5
- Some room to improve with obvious engineering.
- Stakes3 / 5
- Meaningful benefit to many people within a few years.
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: verification (error bars); stakes (mortality, major disease, prevention or cure). Red flags: not randomized; derivative (we apply).
How the score was computed
Score█████░░░░░5.1
Desks place stronger verdicts first, then use this score to order work within the same verdict.
- Merit
- 3.6 / 10
- Adjusted merit
- 3.9 / 10
- Attention
- 28%
- Freshness
- 97%